Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer
Clinical trial NCT04095689 · TERMINATED
Trial details
- NCT number
- NCT04095689
- Sponsor
- The Methodist Hospital Research Institute
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-05-12
- Primary completion
- 2024-06-03
- Enrollment
- 8
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.